Abstract
Introduction

27
Susceptibility to most common human diseases is complex and multifactorial, involving both 28 genetic, environmental and stochastic factors 1 . During the last decade, large-scale genome-29 wide association studies (GWASs) have identified thousands of single nucleotide 30 polymorphisms (SNPs) associated with diseases and related traits, consistent with a 31 polygenic genetic architecture of common disease. These results add useful human-relevant 32 information to drug development, drug repurposing and clinical trial pipelines 2 . Here, we 33 have turned the tables, aiming to identify genetic loci associated with medication-taking. In 34 the context of electronic health record data, medication-use may be an easy route to identify 35 disease-case subjects. However, in clinical practice, it is common that one medication is 36 prescribed for several indications, but conversely, several medications can be prescribed for 37 the same indication. It is likely that medication-use reflects not only similarity between 38 different clinical manifestations 3 and/or comorbidity 4 of diseases but also heterogeneity of 39 clinical manifestation (symptoms and signs) and of intervention response (for example, from 40 lifestyle change to the combination of treatments). 41 42 We hypothesise that genetic variants associated with taking medications categorised based on 43 anatomical and therapeutic classifications may add additional relevant information to 44 understanding the underlying biological mechanism of diseases and drug development 45 approaches. Here, we study genetic variation in current medication-use. We report 505 loci 46 independently associated with medication categories. We explore these GWAS findings for 47 biological mechanisms and as drug targets. We estimate the genetic correlation between the 48 23 medication traits, and with other diseases and traits using published GWAS results. We 49 use Mendelian Randomization to investigate putative causal relationships among diseases 50 and traits. We show that genetic predisposition to common disease predicts likelihood of 51 taking relevant medications, a significant finding in relation to future practice of precision 52 medicine for common disease. 53 54
Results
55
Case-control GWAS of medication-use 56
Medications taken by UKB participants were classified using the Anatomical Therapeutic 57
Chemical Classification System 5 and provided in Figure 1 and S1, Table S1 . Figure S2  58 shows the demographics of participants with medication records. The full phenotype 59 extraction pipeline for UKB participants is summarised in Figure S3 . An overview of 60 analyses is provided in Figure S4 . The medication-use case-control GWASs identify 910 61 within-trait independent SNPs significantly associated (P < 5x10 -8 ) across 23 medication 62 traits (Figure 2 and S5). After applying a more stringent multiple testing threshold (P < 1e-63 8/23) 6 , a total of 505 SNPs remain (Table S2 and S3), with per-trait associations ranging 64 from 0 (C02: hypertensives, N02A:opioids, N06A: antidepressants) to 103 (C09: agents 65 acting on renin-angiotensin system) SNPs. Many of the associated SNPs may simply be a 66 reflection of the primary indication for which the medication is prescribed (Table S4) . For 67 example, C09 medications have therapeutic effect on hypertension; of the 103 independent 68
SNPs associated with C09 medications (P < 10 -8 /23), we identified SNPs previously linked to 69 hypertension (7 SNPs) 7 , systolic blood pressure (32 SNPs) Genetic predisposition to common disease predicts medication-taking 79
We undertook polygenic risk prediction analyses using GWAS summary statistics from 8 80 published disease/traits (Table S5) as discovery data to predict disease risk in 9 medication-81 taking phenotypes as target data. Participants in the UK Biobank with a high GRS for 82 different diseases/traits have a higher odds of taking corresponding medications than those 83 with a low GRS (Figure 3 ; Table S6 ). The top decile of individuals ranked on risk prediction 84 for depression had an odds ratio (OR) of 1.7 in taking anti-depressants compared to the 85 bottom decile. Similarly comparing top and bottom deciles, we find an OR of 3.1 for taking 86 anti-diabetic medication (A10) for individuals ranked on genetic risk for type 2 diabetes and 87 of 3.3 for taking immunosuppressants (L04) for individuals ranked on their genetic risk for 88 rheumatoid arthritis (RA). The OR increased to 5.2 for taking L04 medications specific to 89 RA (Table S1) . All 23 medication-taking traits were enriched in at least one gene set at FDR < 5% 117 (Table S11) Figure 4 and Table S15 . 171 172
Putative causal relationship of diseases for using medication 173
It is reasonable to assume that having a disease is causal for taking the associated medication 174 (rather than reverse causation). Therefore, we used Mendelian Randomisation (MR) in a 175
proof-of-principle analysis to quantify causality. Independent SNPs (P-value < 5E-8) 176 associated with 15 selected diseases/traits (Table S5) (Table S1 ). In total, medications 257 were classified into 1,752 categories, collapsing to 184 subgroups according to the first three 258 ATC levels (Figure 1, S1) . 23 of these medication subgroups (based on participant numbers) 259
were selected for analysis. Genetic risk score (GRS) for UKB individuals were generated for 8 diseases using SNP 277 effect size estimates from published GWAS summary statistics (discovery sample data) 278 (Table S2) . These GRS were used to predict the medication use traits related to these 279 diseases (asthma mapped to two medication use traits). Selection of the discovery samples 280 data was based on relationship to the medication-taking traits, availability of GWAS 281 summary statistics, cohort ancestry and no sample overlap with UKB. GRS were generated 282 for a range of discovery data association P value thresholds (5×10 -8 , 1×10 A  D0  7C  D0  7X  D0  8A  D0  9A  D1  0A  D1  0B  D1  1A  G0  1A  G02   A  G02   B  G02   C  G03A  G03B  G03C  G03D  G03F  G03G   G 03H   G03X  G04B  G04C  H01A  H01B  H01 C  H02 A  H03  A  H0 3B  H0 4A  H0 5B  J0 1A  J0  1B  J0  1C  J0  1D  J0   1E  J0  1F  J0   1G  J0  1M  J0  1X  J0  2A  J0 S0  1C S0  1E S0  1F S0  1G S0  1K S0  1X   S0  2A  S0 2B  S0 2C  S0 3A  S03   B  S03 C V03A V04C V06D  A01A A02A A02B A03A A03B A03C A03 F   A04 A  A05  A A0 6A   A0 7A  A0 7D  A0  7E A0  8A A0  9A A1  0A A1  0B A1  1A A A  D0  7C  D0  7X  D0  8A  D0  9A  D1  0A  D1  0B  D1  1A  G0  1A  G02   A  G02   B  G02   C  G03A  G03B  G03C  G03D  G03F  G03G   G 03H   G03X  G04B  G04C  H01A  H01B  H01 C  H02 A  H03  A  H0 3B  H0 4A  H0 5B  J0 1A  J0  1B  J0  1C  J0  1D  J0   1E  J0  1F  J0   1G  J0  1M  J0  1X  J0  2A  J0 OR and 95% confidence intervals (blue bars) were estimated using logistic regression. The P 510 value in the bottom right hand corner of each plot refers to the P-value threshold in the 511 discovery sample used to generate the GRS. Note: An increased GRS of femoral neck bone 512 mineral density implies a lower density. 
